Audentes therapeutics, inc. (BOLD)
Income statement / TTM
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Sep'15Jun'15
Operating expenses:
Research and development

142,985

135,267

124,316

104,370

97,828

88,778

81,206

75,902

70,830

62,493

55,451

48,770

37,466

28,895

0

0

0

General and administrative

41,345

38,973

35,476

30,002

25,827

22,352

20,136

17,275

15,298

13,898

12,302

11,276

9,747

8,377

0

0

0

Total operating expenses

184,330

174,240

159,792

134,372

123,655

111,130

101,342

93,177

86,128

76,391

67,753

60,046

47,213

37,272

0

0

0

Loss from operations

-184,330

-174,240

-159,792

-134,372

-123,655

-111,130

-101,342

-93,177

-86,128

-76,391

-67,753

-60,046

-47,213

-37,272

0

0

0

Interest income, net

9,305

8,702

7,643

6,030

3,946

2,658

1,479

767

650

545

522

472

359

306

0

0

0

Other expense, net

-463

-500

-492

-479

-141

-96

-77

-74

-61

-53

-88

-94

-169

-101

0

0

0

Net Income (Loss) Attributable to Parent

-175,488

-166,038

-152,641

-128,821

-117,604

-106,322

-97,694

-90,238

-85,539

-75,899

-67,319

-59,668

-47,023

-37,067

0

0

0

Unrealized (losses) gains on investments, net

0

0

0

-

0

0

0

-

0

0

-

-

0

0

0

0

0

Comprehensive loss

-175,295

-165,849

-152,560

-128,881

-117,634

-106,328

-97,759

-90,289

-85,555

-75,939

-67,352

-59,687

-46,999

-37,052

0

0

0

Net loss per share, basic and diluted (USD per share)

-1.00

-1.01

-1.13

-0.84

-0.97

-0.85

-0.74

-0.82

-0.88

-0.87

-0.83

6.63

-0.94

-6.43

-4.85

-5.48

-8.46

Weighted-average number of shares used in computing net loss per share, basic and diluted (in shares)

45,543

44,426

43,625

42,481

37,359

36,935

34,582

29,956

28,388

26,212

21,755

21,910

16,423

2,200

2,159

1,283

640